stockrowAIM ImmunoTech Inc.
AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024.
- Revenue
- +4.00%
- EPS
- +88.3%
- Free cash flow
- −167.5%
Quarter to June 2026, against a year earlier
Follow AIM
Alert me
AIM ImmunoTech Inc. (AIM) Altman Z-score
AIM ImmunoTech Inc.'s Altman Z-score for fiscal 2025 is −113.91, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −113.91 | (36.85) |
| FY2024 | −77.06 | (43.82) |
| FY2023 | −33.24 | (23.94) |
| FY2022 | −9.30 | (32.33) |
| FY2021 | 23.03 | 20.10 |
| FY2020 | 2.93 | 26.30 |
| FY2019 | −23.37 | 11.14 |
| FY2018 | −34.51 | (2.60) |
| FY2017 | −31.90 | (10.18) |
| FY2016 | −21.72 | (6.30) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.51) | — | −0.61 | |
| Retained earnings / total assets | (76.23) | — | −106.73 | |
| EBIT / total assets | (2.02) | — | −6.66 | |
| Market value of equity / total liabilities | 0.12 | — | 0.07 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Distress zone | −113.91 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −266.06 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| XCUR Exicure, Inc. compare | −18.3× |
| EVGN Evogene Ltd. compare | −20.5× |
| APRE Aprea Therapeutics, Inc. compare | −30.1× |
| CRIS Curis, Inc. compare | −87.8× |
| AIM AIM ImmunoTech Inc. | −114× |
| ORGS Orgenesis Inc. compare | −352× |
| CNSP CNS Pharmaceuticals, Inc. compare | — |
| ENVB Enveric Biosciences, Inc. compare | — |
| FBLG FibroBiologics Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets